Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?

Valcamonico, Francesca

Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer? [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Nov 2014 - 3684-5 p. digital

Publication Type: Letter; Comment

1527-7755

10.1200/JCO.2014.56.2017 doi


Adenocarcinoma--drug therapy
Bone Density Conservation Agents--therapeutic use
Bone Neoplasms--drug therapy
Diphosphonates--therapeutic use
Humans
Imidazoles--therapeutic use
Male
Prostatic Neoplasms--drug therapy